ライフサイエンスコーパス: prednisolone

1 3 months followed by azathioprine plus oral prednisolone).

2 azol, methylprednisolone, triamcinolone, and prednisolone.

3 l lines showed an increase in sensitivity to prednisolone.

4 ely associated with the clinical response to prednisolone.

5 d resensitizes B-cell precursor ALL cells to prednisolone.

6 rum levels predicted MOF and the response to prednisolone.

7 reater extents than did alpha-tocopherol and prednisolone.

8 the immunosuppressive effects observed with prednisolone.

9 onic models of inflammation is equivalent to prednisolone.

10 80%) of 64 patients who received 6 months of prednisolone.

11 ere significantly changed by 14 days of oral prednisolone.

12 % of the exacerbations were not treated with prednisolone.

13 ation of different doses of dexamethasone or prednisolone.

14 onses and lower SRE rates than melphalan and prednisolone.

15 ive as a 4-week course of postoperative oral prednisolone.

16 ction of remission with cyclophosphamide and prednisolone.

17 eir response to 2 weeks of therapy with oral prednisolone.

18 with basiliximab, mycophenolate mofetil, and prednisolone.

19 cerbations but not the number requiring oral prednisolone.

20 ccurred in 4 patients and were attenuated by prednisolone.

21 igher-dose (n = 2) cohorts were treated with prednisolone.

22 en including cyclosporine, azathioprine, and prednisolone.

23 hylprednisolone for 3 days, followed by oral prednisolone.

24 acetate for 3 days followed by 1 mg/kg oral prednisolone.

25 detected at 96 hpf in response to 1 mug/L of prednisolone.

26 1:1 ratio) to receive either indomethacin or prednisolone.

27 anercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0

28 f environmentally relevant concentrations of prednisolone (0.1, 1, and 10 mug/L) during zebrafish emb

29 assigned to doxycycline (200 mg per day) or prednisolone (0.5 mg/kg per day) using random permuted b

30 All received a course of tapering oral prednisolone (1 mg/kg prior to taper).

31 uired rescue intervention with icatibant and prednisolone; 1 patient required tracheotomy.

32 el (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily.

33 Minimum doses were prednisolone 10 mg four times a day or intramuscular tet

34 had refractory pregnancy loss(es) were given prednisolone (10 mg) from the time of their positive pre

35 mg, rituximab 375 mg/m(2) on day 1, and oral prednisolone 100 mg on days 1-5, administered every 14 d

36 to the widely used synthetic glucocorticoid prednisolone 2 in vivo.

37 rednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a taper

38 limus (10 ng/mL), everolimus (10 ng/mL), and prednisolone (200 ng/mL).

39 chiolitis, and immediately administered oral prednisolone (30 mg daily).

40 Among 525 patients (48.7%) who received oral prednisolone, 320 (61%) required a dose of more than 40

41 and rituximab 375 mg/m(2) on day 1, and oral prednisolone 40 mg/m(2) on days 1-5, administered every

42 l to evaluate the efficacy of treatment with prednisolone (40 mg daily) or pentoxifylline (400 mg 3 t

43 ittermates were continually treated with GC (prednisolone 5 mg/kg/day via subcutaneous controlled-rel

44 plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy).

45 l standard therapy consisting of intravenous prednisolone (500 mg) plus clemastine (2 mg).

46 ctorial design led to 547 patients receiving prednisolone; 546 were treated with pentoxifylline.

47 n after treatment than of patients not given prednisolone (6%) (OR, 1.70; 95% CI, 1.07-2.69; P = .024

48 Among 23 pregnancies supplemented with prednisolone, 9 women had 14 live births (61%), includin

49 (0)(0)(0), (2)(0)(0)(0), PEG(3)(4)(0)(0) and prednisolone, a model drug cleared from the lungs within

50 regimens consisted of postoperative topical prednisolone acetate (PA) alone or with a nonsteroidal a

51 omized to ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA,

52 Three agents-prednisolone acetate (PA), triamcinolone acetonide (TA),

53 coids, beclomethasone dipropionate (BDP) and prednisolone acetate (PDNA), on force production in isol

54 51, 95% CI = 1.43-147.23) and use of topical prednisolone acetate 1% compared with dexamethasone 0.1%

55 ed IOP post DALK included the use of topical prednisolone acetate 1% compared with dexamethasone 0.1%

56 intensive, potent, topical corticosteroids: prednisolone acetate 1% eye drops with or without dexame

57 Prednisolone acetate 1% solution (PRED FORTE) was used a

58 mized to receive placebo (artificial tears), prednisolone acetate 1%, or ketorolac tromethamine 0.5%

59 reement was less than 15% for 4 medications (prednisolone acetate [generic], betaxolol HCl [Betoptic;

60 amethasone (DEX), triamcinolone acetate, and prednisolone acetate by TaqMan PCR.

61 Prednisolone acetate eye drops 1% 5 times daily for the

62 After an internal change of therapy regimen: Prednisolone acetate eye drops 1% hourly for the first p

63 Topical prednisolone acetate interfered with viral clearance, an

64 ord cows (n = 4) were subjected to uniocular prednisolone acetate treatment for 6 weeks.

65 A single GC IDI (25 mg prednisolone acetate) during discography (n = 67) or dis

66 er the onset of keratitis with albumin, VIG, prednisolone acetate, trifluridine, or combinations ther

67 Prednisolone administration attenuated ConA- and alpha-G

68 the results have been controversial, and how prednisolone affects liver disease progression remains u

69 older patients using medium to high doses of prednisolone, alendronate treatment was associated with

70 Mice were treated with prednisolone, alendronate, and both in combination for u

71 Prednisolone alone and in combination with alendronate e

72 ntoxifylline and prednisolone, compared with prednisolone alone, did not result in improved 6-month s

73 In addition, administration of prednisolone also enhanced acetaminophen-, ethanol-, or

74 Prednisolone also inhibited ACTH and cortisol secretion

75 Treating mice with prednisolone also suppressed inflammatory responses in a

76 ks compared with 92 (91%) of 101 patients on prednisolone, an adjusted difference of 18.6% (90% CI 11

77 ctions (24 hpf) was significantly reduced by prednisolone and 0.1 mug/L increased the distance embryo

78 ns, treatment failures occurred in 15% given prednisolone and 2% of those given placebo (P = 0.04).

79 77%) of 62 patients who received 3 months of prednisolone and 51 (80%) of 64 patients who received 6

80 olone-matched placebo, a group that received prednisolone and a pentoxifylline-matched placebo, a gro

81 Herein, we evaluated prednisolone and alendronate for their therapeutic poten

82 Combined treatment of prednisolone and alendronate provided best improvement i

83 r the original diagnosis is on a low dose of prednisolone and azathioprine, with no signs of relapse.

84 As the disease was successfully treated with prednisolone and budesonide, the model will be helpful t

85 enal function was significantly lower in the prednisolone and chlorambucil group than in the supporti

86 t in all three groups but were higher in the prednisolone and chlorambucil group than in the supporti

87 etory renal function, 6 months' therapy with prednisolone and chlorambucil is the treatment approach

88 y assigned 108 patients, 33 of whom received prednisolone and chlorambucil, 37 ciclosporin, and 38 su

89 tment plus 6 months of alternating cycles of prednisolone and chlorambucil, or supportive treatment p

90 ensu stricto was dramatically reduced in the prednisolone and combined IS drug groups.

91 Oral prednisolone and indomethacin had similar analgesic effe

92 Both prednisolone and M. indicus pranii, each as compared wit

93 times a day (n=133) for 28 days, or 40 mg of prednisolone and matching placebo (n=137) for 28 days.

94 Surprisingly and in contrast to prednisolone and MPA, neither tacrolimus nor everolimus

95 Prednisolone and pentoxifylline are both recommended for

96 tched placebo, or a group that received both prednisolone and pentoxifylline.

97 ival was not different in the pentoxifylline-prednisolone and placebo-prednisolone groups (69.9% [95%

98 e detection of boldenone, or its conjugates, prednisolone and prednisone.

99 In vitro, prednisolone and the pharmacologic GR antagonist mifepri

100 ignificantly different in the pentoxifylline-prednisolone and the placebo-prednisolone groups (8.4% [

101 rimary outcome between patients who received prednisolone and those who received placebo (23.8% and 2

102 utcomes of patients treated with and without prednisolone, and identified risk factors for developmen

103 cantly suppressed by tacrolimus, everolimus, prednisolone, and MPA (P<0.05).

104 onse was affected by tacrolimus, everolimus, prednisolone, and mycophenolic acid (MPA) in clinically

105 e preferentially inhibited by tacrolimus and prednisolone, and not by everolimus.

106 uding plasmapheresis, immunosuppression with prednisolone, and numerous transfusions.

107 tients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 p

108 the same era treated with intravenous methyl prednisolone, and with a contemporaneous UK renal transp

109 trol; (2) 5 mg/kg/day LANZO; (3) 5 mg/kg/day prednisolone; and (4) combined treatment of 5 mg/kg/day

110 th groups received equal cumulative doses of prednisolone (approximately 3360 mg/m(2)).

111 Patients with SAH given prednisolone are at greater risk for developing serious

112 The two enhancers, dexamethasone and prednisolone, are synthetic glucocorticoids that potenti

113 idated against prescription filling records, prednisolone assay, and concordance interview.

114 suggest that combined treatment of LANZO and prednisolone attenuates some components of dystrophic pa

115 (cyclophosphamide, doxorubicin, vincristine, prednisolone)-based chemotherapy were prospectively foll

116 the GCs corticosterone, hydrocortisone, and prednisolone, but not the synthetic GC dexamethasone.

117 ckdown increased sensitivity specifically to prednisolone by increasing the levels of the glucocortic

118 nfluorinated glucocorticoids, prednisone and prednisolone, can be used throughout pregnancy, although

119 Prednisolone cannot be routinely recommended for all you

120 Oral prednisolone caused a similar degree of suppression of e

121 Oral prednisolone changes the transcriptomic profile of the A

122 lophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in p

123 lophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n = 64, 26%) o

124 oxydaunorubicin, vincristine, and prednisone/prednisolone (CHOP-14) was determined by ELISA in 20 eld

125 nvestigated before and after 2 weeks of oral prednisolone (Clintrials.gov NCT00331058 and NCT00327197

126 gation of the clinical efficacy of LANZO and prednisolone combined treatment regimens in dystrophic p

127 is, 4-week treatment with pentoxifylline and prednisolone, compared with prednisolone alone, did not

128 G(2)(0)(0)(0) conjugates reduced the maximum prednisolone concentration in the perfusate (Cmax) by 3.

129 20 min when the free drug was administered, prednisolone concentrations were still quantifiable afte

130 With the exception of PEG(3)(4)(0)(0)-prednisolone, conjugates did not induce a significant la

131 s, which is an mTOR inhibitor (P/EVL; n=10), prednisolone/CsA (P/CsA; n=7), or prednisolone/MPS (P/MP

132 ied renal transplant recipients treated with prednisolone, cyclosporine A (CsA), and mycophenolate so

133 A dose of 12.5-25.0 mg prednisolone daily or equivalent leads to rapid improvem

134 subjects and patients with mild, severe, and prednisolone-dependent asthma under stable conditions an

135 nts with severe asthma, and 30 patients with prednisolone-dependent asthma) parameters of inflammatio

136 erence), and one also denied nonadherence to prednisolone despite nonadherent blood level.

137 igher proportion (10%) of patients receiving prednisolone developed an infection after treatment than

138 Prednisolone disrupted fecal microbiota community struct

139 Use of oral prednisolone during the early acute phase of dengue infe

140 ng </=5 mg (n = 64) and >5 mg (n = 53) daily prednisolone-equivalent doses.

141 ion followed by double therapy consisting of prednisolone/everolimus, which is an mTOR inhibitor (P/E

142 lophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop

143 Prednisolone fast feedback was only reduced by glucocort

144 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg

145 ith nephrotic syndrome to either 3 months of prednisolone followed by 3 months of placebo (n=74) or 6

146 Subjects in the standard arm received prednisolone for 2 weeks, whereas in the biomarker-direc

147 ily or intermittent (10 days on/10 days off) prednisolone for a mean duration of treatment of 4 years

148 non-inferior to standard treatment with oral prednisolone for short-term blister control in bullous p

149 hils during the clinical course and received prednisolone for the same, which resulted in the resolut

150 randomly assigned to doxycycline and 121 to prednisolone from 54 UK and seven German dermatology cen

151 more minor adverse events than those in the prednisolone group (19% vs. 6%; P < 0.001).

152 Mean symptom severity was 1.99 points in the prednisolone group and 2.16 points in the placebo group

153 (interquartile range [IQR], 3-8 days) in the prednisolone group and 5 days (IQR, 3-10 days) in the pl

154 For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breat

155 the pentoxifylline-prednisolone and placebo-prednisolone groups (69.9% [95% CI, 62.1%-77.7%] vs 69.2

156 pentoxifylline-prednisolone and the placebo-prednisolone groups (8.4% [95% CI, 4.8%-14.8%] vs 15.3%

157 Prednisolone improved muscle pathology with significant

158 Abiraterone acetate plus prednisolone improves survival in men with relapsed pros

159 oss(es) who were treated with early low-dose prednisolone in addition to aspirin and heparin.

160 BMS-986126 also demonstrated synergy with prednisolone in assays of TLR7- and TLR9-induced IFN tar

161 o the renal benefits observed with high-dose prednisolone in control mice.

162 The use of systemic prednisolone in eyes with vasculitis was associated with

163 HDAC inhibitor SAHA restores sensitivity to prednisolone in TBL1XR1-depleted cells.

164 s/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirme

165 in score were observed with indomethacin and prednisolone in the ED (approximately 10 mm [rest] and 2

166 nd 41 mg/kg) of naproxcinod and 0.9 mg/kg of prednisolone in their food for 9 months.

167 ) colitis model, and compared favorably with prednisolone in this model and supports its potential us

168 oral dexamethasone (equivalent to 40 mg/day prednisolone) in 22 current, 21 never and 10 ex-smokers

169 mortality in patients with SAH treated with prednisolone, independent of model for end-stage liver d

170 In patients who did not receive prednisolone, infection was not independently associated

171 previously taken alendronate at the time of prednisolone initiation.

172 Prednisolone is a commonly prescribed synthetic glucocor

173 Prednisolone is a corticosteroid that has been used to t

174 Prednisolone is a safe, effective first-line option for

175 Prednisolone is advocated for treatment of SAH, but can

176 onate treatment in older patients using oral prednisolone is associated with decreased hip fracture r

177 le is forbidden in the European Union, while prednisolone is permitted for therapeutic purposes.

178 However, relapses are common when prednisolone is tapered.

179 We found that dexamethasone and prednisolone, like other glucocorticoids, suppress zebra

180 1-2.7 years in comparison with prednisone or prednisolone (log-rank p<0.012).

181 100% of these patients achieving "success" (prednisolone </=10 mg and sustained control) with the ne

182 s with respect to the eventual initiation of prednisolone maintenance and/or other immunosuppressive

183 eived a pentoxifylline-matched placebo and a prednisolone-matched placebo, a group that received pred

184 , a group that received pentoxifylline and a prednisolone-matched placebo, or a group that received b

185 may become prednisolone sensitive indicating prednisolone may be an effective adjuvant therapy in som

186 Prednisolone may lead to a prompt amelioration of eosino

187 ions given placebo compared with those given prednisolone (mean difference, 0.45; 95% confidence inte

188 tor in macrophages and neutrophils abolished prednisolone-mediated exacerbation of hepatotoxin-induce

189 diagnosed with PG and treated with high-dose prednisolone, methotrexate and cyclosporine.

190 roid cortivazol, other particulate steroids (prednisolone, methylprednisolone, and triamcinolone) cau

191 Results With prednisolone, methylprednisolone, or triamcinolone, bloo

192 Prednisolone might be beneficial in a subgroup of childr

193 starting doxycycline and 36% (41 of 113) for prednisolone (mITT), an adjusted difference of 19.0% (95

194 methasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagno

195 VL; n=10), prednisolone/CsA (P/CsA; n=7), or prednisolone/MPS (P/MPS; n=9).

196 Mice were treated for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combi

197 dney transplantation in recipients receiving prednisolone, mycophenolate, and tacrolimus.

198 lone (n = 547) and patients not treated with prednisolone (n = 545) using logistic regression.

199 valuated separately in patients treated with prednisolone (n = 547) and patients not treated with pre

200 were taken before and after 14 days of oral prednisolone (n = 6) or placebo (n = 6).

201 by 3 months of placebo (n=74) or 6 months of prednisolone (n=76), and median follow-up was 47 months.

202 ients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant eff

203 were more frequent in patients treated with prednisolone (odds ratio [OR], 1.27; 95% confidence inte

204 to receive either a combination of 40 mg of prednisolone once a day and 400 mg of pentoxifylline 3 t

205 The AIH could be treated with prednisolone or adoptive transfer of polyspecific Tregs.

206 eeks, whereas in the biomarker-directed arm, prednisolone or matching placebo was given according to

207 independently associated with total or free prednisolone or MPA exposure.

208 Prednisolone or pentoxifylline is recommended for severe

209 ign to evaluate the effect of treatment with prednisolone or pentoxifylline.

210 probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. ind

211 subcutaneous insertion of long-term release prednisolone or placebo pellets.

212 or at least 4 weeks and were taking a stable prednisolone or prednisone dose to receive 300 mg of mep

213 placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day dur

214 tion (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot).

215 , cyclophosphamide, vindesine, bleomycin and prednisolone]: OR 1.70; P < .04), PFS (ACVBP: HR 0.72; P

216 on of clinical scores was observed with oral prednisolone (P < 0.0001) but not for the CCR4 inhibitor

217 iated TEC lysis was efficiently inhibited by prednisolone (P<0.05).

218 olone versus 7% of those who did not receive prednisolone (P=0.002).

219 -Webster mice were treated with slow-release prednisolone pellets at 1.4, 2.8, and 5.6 mg/kg/d for 28

220 Whilst administration of long-term release prednisolone pellets provided a robust GIO animal model

221 o group, and 13% (35 of 260 patients) in the prednisolone-pentoxifylline group.

222 long-circulating liposomes (LCL) containing prednisolone phosphate (PLP-LCL) in a mouse model of art

223 me dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2).

224 acebo group, 14% (38 of 266 patients) in the prednisolone-placebo group, 19% (50 of 258 patients) in

225 We found that prednisolone plasma levels in patients with CRPC were su

226 Patients were treated with oral prednisolone plus full supportive measures.

227 mal treatment for patients with severe AH is prednisolone, possibly in combination with N-acetyl cyst

228 e; and (4) combined treatment of 5 mg/kg/day prednisolone (PRED) and 5 mg/kg/day LANZO.

229 ayers were treated with dexamethasone (DEX), prednisolone (PRED), or GW870086X for 5 days and then as

230 xed glucocorticoid/mineralocorticoid agonist prednisolone produced rapid inhibition of ACTH and corti

231 lophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) to uncover molecular subgroups lin

232 citabine, cyclophosphamide, vincristine, and prednisolone (R-GCVP) in patients considered unfit for a

233 otein kinase (MAPK) pathway as a mediator of prednisolone resistance in pediatric ALL.

234 cently implicated in B-ALL proliferation and prednisolone resistance, and the novel target CTNND1, en

235 cursor ALL cells and induces stroma-mediated prednisolone resistance.

236 er for methylprednisolone, triamcinolone, or prednisolone, respectively, vs 21.0, 21.4, and 19.1 capi

237 by MRD >/= 1 x 10(-3) at week 12 and/or poor prednisolone response, BCR-ABL1, MLL gene rearrangements

238 Treatment with prednisolone resulted in an immediate response with rapi

239 Dck-defective leukemic cells may become prednisolone sensitive indicating prednisolone may be an

240 nes were established with one clone becoming prednisolone sensitive.

241 hairpin RNA screen to identify mediators of prednisolone sensitivity in ALL cell lines.

242 glucocorticoid resistance, we determined the prednisolone sensitivity of primary leukemia cells from

243 upplements, antibiotics, antihistamines, and prednisolone significantly more often on multivariate an

244 This multicenter trial compared 1.0% prednisolone sodium phosphate to placebo in the treatmen

245 nation of suboptimal doses of BMS-986126 and prednisolone, suggesting the potential for steroid spari

246 The intravenous prednisolone suppression test provides a powerful new to

247 Two 20-mg prednisolone tablets (n = 199) or matched placebo (n = 2

248 Prednisolone, tacrolimus, and mycophenolate mofetil modi

249 classified colitis n = 11) that were on oral prednisolone therapy about to be discontinued.

250 There was no association between prednisolone therapy and infection during treatment (OR,

251 dose (0.5 mg/kg) or high-dose (2 mg/kg) oral prednisolone therapy for 3 days in Vietnamese patients a

252 Oral prednisolone therapy significantly reduced the median nu

253 Prednisolone therapy, as compared with placebo, was asso

254 ed infection that developed within 7 days of prednisolone therapy, independent of Model for End-Stage

255 nd mDC shows a differential response to oral prednisolone therapy.

256 Environmentally relevant concentrations of prednisolone therefore alter early zebrafish ontogeny an

257 patients at high risk of infection if given prednisolone; these data could be used to select therapi

258 mbers MEK2 and MEK4 increased sensitivity to prednisolone through distinct mechanisms.

259 The addition of first-trimester low-dose prednisolone to conventional treatment is worthy of furt

260 We report that administration of prednisolone to mice increased reactive oxygen species (

261 nd glucocorticoids (GCs) (ie, dexamethasone, prednisolone) to trigger apoptosis in ALL cells.

262 phy revealed that contrary to C57BL/6J mice, prednisolone treated CD1 mice developed osteoporosis.

263 l clearance, and ocular disease rebounded in prednisolone-treated groups.

264 alendronate after at least 3 months of oral prednisolone treatment (>/=5 mg/d) were identified.

265 os hatched significantly increased following prednisolone treatment (1 and 10 mug/L), while growth an

266 Prolonged prednisolone treatment for the initial episode of childh

267 conclusion, in this trial, extending initial prednisolone treatment from 3 to 6 months without increa

268 verse effects, we have studied the effect of prednisolone treatment in dystrophin/utrophin double kno

269 d flow cytometric analyses demonstrated that prednisolone treatment inhibited hepatic macrophage and

270 to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-s

271 the current study we examined the effect of prednisolone treatment on several models of liver injury

272 Prednisolone treatment prevents T/NKT cell hepatitis but

273 is related to upregulation of mTOR, and that prednisolone treatment reduces the expression of mTOR an

274 However, prednisolone treatment was unable to improve the myogene

275 ce showed no differences between placebo and prednisolone treatment.

276 er a median of 5 days (range, 2 to 35) after prednisolone treatment.

277 dition, the long-term detrimental effects of prednisolone typically seen in mdx skeletal and heart fu

278 erence of 18.6% (90% CI 11.1-26.1) favouring prednisolone (upper limit of 90% CI, 26.1%, within the p

279 difference between the groups in the risk of prednisolone use for exacerbation was found (hazard rati

280 occurred in 13% of the patients treated with prednisolone versus 7% of those who did not receive pred

281 amethasone (CTD; intensive) or melphalan and prednisolone versus attenuated oral CTD (CTDa; nonintens

282 l [CI], 0.77 to 1.49; P=0.69), and that with prednisolone was 0.72 (95% CI, 0.52 to 1.01; P=0.06).

283 Prednisolone was associated with a reduction in 28-day m

284 ic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher ra

285 Before low-dose prednisolone was given as treatment, 4 (4%) of 97 pregna

286 Therefore, immunosuppressive treatment with prednisolone was started.

287 Interestingly, prednisolone was the most powerful inhibitor of NK cell

288 Prednisolone was therefore seen to be effective for trea

289 Moreover, while prednisolone was undetectable in the perfusion solution

290 limus, mycophenolic acid, and total and free prednisolone were estimated at month 1 posttransplant us

291 conditions wherein flunixin of meglumine and prednisolone were marginally effective.

292 of cyclosporine, mycophenolate mofetil, and prednisolone were well tolerated and equally effective i

293 articularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr

294 ions after treatment than patients not given prednisolone, which may offset its therapeutic benefit.

295 t contraction was differentially affected by prednisolone while heart rate and oxygen consumption bot

296 ive cases, oral NSAIDs were replaced by oral prednisolone with cyclosporine, azathioprine, or mycophe

297 logues, fluorouracil, azathioprine, and oral prednisolone with improved outcomes for vitiligo.

298 which was at least as effective as high-dose prednisolone with potentially fewer adverse effects.

299 ut alendronate use from 6076 patients taking prednisolone with the same dose and treatment time crite

300 tenuated disease as effectively as high-dose prednisolone without the systemic immunosuppressive effe